Intravacc offers four complementary vaccine development platforms: bacterial vaccines, viral vaccines, conjugate vaccines, and E.coli expressed ...
The COVID-19 vaccine was a triumph of science. Governments, researchers, and vaccine manufacturers worked in tandem to ...
Vaccine development is traditionally driven by financial return opportunities for investors, disease outbreaks, and a specific focus on emerging diseases. However, a new systematic, transparent, and ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. While the media's attention has focused on unproven links between ...
A new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists and IAVI has the potential to protect humans from developing HIV infection and AIDS. This HIV ...
WHO-origin Master and Working Cell Banks provide vaccine developers with a ready-to-use Vero cell substrate for licensing, purchase, and integrated CDMO programs ...
The MVA platform is uniquely designed to incorporate multiple antigens into a single vaccine. This versatility allows GeoVax to develop vaccines targeting multiple aspects of a single pathogen or ...
Emerging and neglected tropical diseases continue to pose major public health challenges across low- and middle-income ...
Vaccines are the most efficacious means of minimizing the impact of infectious diseases on the human population. The challenges and importance of making vaccines that will meet FDA approval have never ...
mRNA technology is enabling an entirely new HIV vaccine strategy that, for the first time, successfully primes the immune system toward broadly neutralizing antibodies in humans. The TB vaccine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results